Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Kane William	2. Issuer Name and Ticker or Trading Symbol Citius Pharmaceuticals, Inc. [ CTXR ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR	3. Date of Earliest Transaction (MM/DD/YYYY) 10/6/2020
(Street) CRANFORD, NJ 07016 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Common Stock (1)	$1.01	10/6/2020		A		35000		(1)	10/6/2030	Common Stock	35000	$0	35000	D
Options to Purchase Common Stock (2)	$1.39							(2)	7/7/2030	Common Stock	25000		25000	D
Options to Purchase Common Stock (3)	$0.67							(3)	10/8/2029	Common Stock	25000		25000	D
Options to Purchase Common Stock (4)	$1.62							(4)	9/4/2028	Common Stock	15000		15000	D
Options to Purchase Common Stock (5)	$3.45							(5)	9/13/2027	Common Stock	10000		10000	D
Options to Purchase Common Stock (6)	$0.015							(6)	3/28/2024	Common Stock	12071		12071	D
Options to Purchase Common Stock (7)	$12							(7)	6/23/2026	Common Stock	13334		13334	D

Explanation of Responses:
(1)	The options vest in full on October 6, 2021.
(2)	The options vest in full on July 7, 2021.
(3)	The options vest in full on October 8, 2020.
(4)	The options vest in full on September 4, 2019.
(5)	The options vest in full on September 13, 2018.
(6)	The options vested in 1/3 increments over a three-year period with the first installment vesting on March 28, 2015.
(7)	The options vested in full on the first anniversary of the date of grant.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Kane William C/O CITIUS PHARMACEUTICALS, INC. 11 COMMERCE DRIVE, 1ST FLOOR CRANFORD, NJ 07016	X

Signatures
/s/ Alexander M. Donaldson, by power of attorney		10/8/2020
**Signature of Reporting Person		Date